.Pharmacolibrary.Drugs.ATC.A.A10XX01 .Pharmacolibrary.Drugs.ATC.A.A10XX01| name: | Teplizumab | |
| ATC code: | A10XX01 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 826 | mg |
| volume of distribution: | 7 | L |
| clearance: | 0.275 | L/h |
| other parameters in model implementation | ||
Teplizumab is a humanized anti-CD3 monoclonal antibody that modulates T lymphocyte function by binding to the CD3 epsilon chain. It has been developed to delay the onset of type 1 diabetes (T1D) in at-risk individuals with evidence of beta cell autoimmunity but not yet overt diabetes. Teplizumab received FDA approval in 2022 for delaying clinical type 1 diabetes in at-risk pediatric and adult patients.
Pharmacokinetic parameters estimated for healthy adults and subjects with type 1 diabetes based on publicly available data and FDA label, as no detailed publication with full popPK model available.